490 related articles for article (PubMed ID: 25958815)
1. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
Kumalo HM; Bhakat S; Soliman ME
Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
[TBL] [Abstract][Full Text] [Related]
2. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
[TBL] [Abstract][Full Text] [Related]
3. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
4. Heat-Shock Protein 90-Targeted Nano Anticancer Therapy.
Rochani AK; Ravindran Girija A; Borah A; Maekawa T; Sakthi Kumar D
J Pharm Sci; 2016 Apr; 105(4):1454-66. PubMed ID: 26886301
[TBL] [Abstract][Full Text] [Related]
5. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
6. HSP90 inhibitors: current development and potential in cancer therapy.
Sidera K; Patsavoudi E
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
[TBL] [Abstract][Full Text] [Related]
7. Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.
Casale E; Amboldi N; Brasca MG; Caronni D; Colombo N; Dalvit C; Felder ER; Fogliatto G; Galvani A; Isacchi A; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Casuscelli F
Bioorg Med Chem; 2014 Aug; 22(15):4135-50. PubMed ID: 24980703
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
10. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
11. Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy.
Proia DA; Kaufmann GF
Cancer Immunol Res; 2015 Jun; 3(6):583-9. PubMed ID: 25948551
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
14. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
15. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
Messaoudi S; Peyrat JF; Brion JD; Alami M
Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
[TBL] [Abstract][Full Text] [Related]
16. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications.
Özgür A; Tutar Y
Anticancer Agents Med Chem; 2016; 16(3):280-90. PubMed ID: 26295332
[TBL] [Abstract][Full Text] [Related]
17. Recent update on discovery and development of Hsp90 inhibitors as senolytic agents.
Dutta Gupta S; Pan CH
Int J Biol Macromol; 2020 Oct; 161():1086-1098. PubMed ID: 32561284
[TBL] [Abstract][Full Text] [Related]
18. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
Jhaveri K; Modi S
Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 inhibitors as therapeutic agents.
Gomez-Monterrey I; Sala M; Musella S; Campiglia P
Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
[TBL] [Abstract][Full Text] [Related]
20. TRAP1: a viable therapeutic target for future cancer treatments?
Lettini G; Maddalena F; Sisinni L; Condelli V; Matassa DS; Costi MP; Simoni D; Esposito F; Landriscina M
Expert Opin Ther Targets; 2017 Aug; 21(8):805-815. PubMed ID: 28664757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
